High hopes for US cannabis businesses | DW News

Key Concepts

• Schedule I Drug: A classification under the Controlled Substances Act with no accepted medical use and a high potential for abuse (e.g., heroin, LSD – previously cannabis).
• Schedule III Drug: A classification with accepted medical use and moderate to low potential for abuse (e.g., steroids, painkillers with codeine – cannabis’s new potential classification).
• Rescheduling: The process of moving a drug to a different schedule under the Controlled Substances Act, impacting its legal status and regulations.
• Decriminalization: Reducing penalties for possession of a substance, often to a fine rather than jail time.
• Legalization: Removing all prohibitions on the production, sale, and possession of a substance.
• CBD (Cannabidiol): A non-psychoactive compound found in cannabis, believed to have therapeutic benefits.

Cannabis Rescheduling: Impact of the Executive Order

The recent executive order signed by US President Donald Trump initiates a significant shift in the federal classification of cannabis, potentially unlocking substantial growth for the US cannabis industry. Currently classified as a Schedule I drug since 1971 – alongside heroin and LSD – cannabis is slated to be moved to Schedule III, aligning it with substances like steroids and painkillers containing codeine. This change stems from growing pressure and advocacy, as highlighted by the President’s statement: “We have uh people begging for me to do this, people that are in great pain.”

The Implications of Rescheduling

The primary effect of rescheduling is to acknowledge a potential medical use for cannabis, a departure from the long-held federal stance. This has several key implications:

• Reduced Tax Burden: Cannabis companies currently face significant tax disadvantages due to their Schedule I status, specifically Section 280E of the Internal Revenue Code which prohibits businesses trafficking in controlled substances from deducting normal business expenses. Rescheduling could alleviate this burden, increasing profitability.
• Increased Investment: The current legal ambiguity discourages institutional investment. A Schedule III classification is expected to encourage greater investment into the cannabis sector.
• Facilitated Medical Research: The Schedule I classification has historically hindered comprehensive medical research into the potential benefits of cannabis. Rescheduling will streamline the research process, allowing for more robust studies.
• CBD Reimbursement Pilot Program: The new regulations pave the way for a pilot program to reimburse Medicare patients for products containing CBD, expanding access to this potential therapeutic option.

Market Reaction and Remaining Challenges

Initial market reaction to the announcement was positive, with cannabis-related stocks experiencing a surge. However, these gains were quickly relinquished due to the absence of a mandate addressing cannabis banking. This highlights a critical ongoing challenge: despite state-level legalization in over half of US states, federal law still prohibits marijuana. This discrepancy creates a “gray area” where cannabis companies face risks of federal enforcement and difficulties accessing traditional banking services. As stated in the report, “It doesn't legalize marijuana in any way, shape, or form.”

Current Market Size and Potential Growth

Despite the legal complexities, the US cannabis market is already substantial, generating approximately $32 billion annually. While the executive order does not represent full nationwide legalization, it is anticipated to stimulate significant growth within the existing framework.

Legal Landscape & Definitions

It’s important to differentiate between legalization and decriminalization. Legalization removes all prohibitions on cannabis, while decriminalization reduces penalties for possession. Currently, a patchwork of state laws exists, ranging from full legalization to decriminalization to complete prohibition. The federal government’s continued prohibition creates a conflict with these state laws.

Conclusion

The rescheduling of cannabis represents a pivotal moment for the US cannabis industry. While not a complete solution to the existing legal challenges, it removes a significant barrier to growth, fostering increased investment, research, and potentially, patient access. The lack of banking reform remains a key obstacle, but the shift in federal classification signals a growing acceptance of cannabis’s potential benefits and a move towards a more rational regulatory framework.